Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cue Biopharma (CUE) EBT Margin (2018 - 2025)

Historic EBT Margin for Cue Biopharma (CUE) over the last 8 years, with Q3 2025 value amounting to 343.09%.

  • Cue Biopharma's EBT Margin fell 891300.0% to 343.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 525.1%, marking a year-over-year decrease of 691500.0%. This contributed to the annual value of 429.4% for FY2024, which is 4720200.0% up from last year.
  • Per Cue Biopharma's latest filing, its EBT Margin stood at 343.09% for Q3 2025, which was down 891300.0% from 285.61% recorded in Q2 2025.
  • Cue Biopharma's 5-year EBT Margin high stood at 95.58% for Q4 2021, and its period low was 50800.0% during Q2 2022.
  • Over the past 5 years, Cue Biopharma's median EBT Margin value was 705.07% (recorded in 2024), while the average stood at 4946.68%.
  • As far as peak fluctuations go, Cue Biopharma's EBT Margin tumbled by -504247200bps in 2022, and later skyrocketed by 498627400bps in 2023.
  • Quarter analysis of 5 years shows Cue Biopharma's EBT Margin stood at 95.58% in 2021, then plummeted by -9763bps to 9426.49% in 2022, then soared by 92bps to 709.88% in 2023, then grew by 16bps to 592.83% in 2024, then surged by 42bps to 343.09% in 2025.
  • Its EBT Margin was 343.09% in Q3 2025, compared to 285.61% in Q2 2025 and 2881.0% in Q1 2025.